Halozyme to Participate in Upcoming Investor Conferences
Halozyme to Participate in Upcoming Investor Conferences
SAN DIEGO, May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences:
圣地亚哥，2024年5月8日 /PRNewswire/ — Halozyme Therapeutics, Inc.（纳斯达克股票代码：HALO）（“Halozyme”）今天宣布，首席财务官妮可·拉布罗斯计划在以下投资者会议上主持和主持投资者会议：
|
Event: |
The Citizens JMP Life Sciences Conference | |||
|
Format: |
Fireside Chat and 1x1 Meetings | |||
|
Presentation Date: |
Tuesday, May 14, 2024 | |||
|
Presentation Time: |
7:00 a.m. PT / 10:00 a.m. ET | |||
|
Location: |
New York, NY | |||
| Event: |
Benchmark 2024 Healthcare House Call Virtual Conference | |||
|
Format: |
1x1 Meetings | |||
|
Date: |
Tuesday, May 21 and Wednesday, May 22, 2024 |
|
活动： |
Citizens JMP 生命科学会议 | |||
|
格式： |
炉边聊天和 1x1 会议 | |||
|
演示日期： |
2024 年 5 月 14 日，星期二 | |||
|
演讲时间： |
太平洋时间上午 7:00 /美国东部时间上午 10:00 | |||
|
地点： |
纽约，纽约 | |||
| 活动： |
Benchmark 2024 医疗保健公司电话会议虚拟会议 | |||
|
格式： |
1x1 会议 | |||
|
日期： |
2024 年 5 月 21 日星期二和 5 月 22 日星期三 |
A live audio webcast of the JMP presentation will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
JMP演示文稿的网络直播将在公司网站的投资者关系部分播出。网络音频广播的重播将在会议结束后的90天内提供。
About Halozyme
关于 Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme是一家生物制药公司，致力于提供颠覆性解决方案，以改善新兴和成熟疗法的患者体验和疗效。作为 ENHANZE 的创新者 采用专有酶rHupH20的药物递送技术，Halozyme的商业验证解决方案用于促进注射药物和液体的皮下输送，目标是减轻患者的治疗负担。Halozyme在全球100多个市场使用了七种商业化产品，在上市后使用了超过80万名患者的生活，并已授权其ENHANZE 向领先的制药和生物技术公司提供技术，包括罗氏、武田、辉瑞、詹森、艾伯维、礼来、百时美施贵宝、argenx、**** Healthcare、Chugai Pharmaceutical和Acumen Pharmicals。
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme还使用其先进的自动注射器技术为自己或与合作伙伴开发、制造和商业化药物器械组合产品，这些产品旨在提供商业或功能优势，例如提高便利性、可靠性和耐受性，增强患者的舒适度和依从性。该公司有两种商业专有产品，Hylenex 还有 XYOSTED，与包括梯瓦制药和Idorsia Pharmicals在内的多家制药公司合作了商业产品和正在进行的产品开发计划。
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
Halozyme总部位于加利福尼亚州圣地亚哥，在新泽西州尤因和明尼苏达州明尼顿卡设有办事处。明尼顿卡也是其运营设施的所在地。
For more information visit and connect with us on LinkedIn and Twitter.
欲了解更多信息，请访问我们的领英和推特并联系我们。
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]
联系人：
Bui 有轨电车
投资者关系和企业传播副总裁
609-359-3016
[电子邮件保护]
Samantha Gaspar
Teneo
212-886-9356
[email protected]
萨曼莎·加斯帕
Teneo
212-886-9356
[电子邮件保护]
SOURCE Halozyme Therapeutics, Inc.
来源 Halozyme Therapeutics, Inc.
译文内容由第三方软件翻译。